Voss Capital LP Boosts Stake in Rein Therapeutics Inc. $RNTX

Voss Capital LP boosted its stake in shares of Rein Therapeutics Inc. (NASDAQ:RNTX) by 59.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,243,969 shares of the company’s stock after buying an additional 1,577,437 shares during the period. Voss Capital LP owned 16.14% of Rein Therapeutics worth $4,923,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Geode Capital Management LLC purchased a new stake in shares of Rein Therapeutics during the 2nd quarter valued at $344,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Rein Therapeutics during the 2nd quarter valued at $68,000. Cable Car Capital LP purchased a new stake in shares of Rein Therapeutics during the 2nd quarter valued at $588,000. Vanguard Group Inc. lifted its holdings in shares of Rein Therapeutics by 32.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock valued at $1,338,000 after purchasing an additional 284,300 shares during the last quarter. Finally, Prosight Management LP lifted its holdings in shares of Rein Therapeutics by 32.7% during the 3rd quarter. Prosight Management LP now owns 567,898 shares of the company’s stock valued at $650,000 after purchasing an additional 139,979 shares during the last quarter. Hedge funds and other institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Price Performance

NASDAQ RNTX opened at $0.96 on Friday. The stock’s fifty day moving average price is $1.27 and its 200 day moving average price is $1.28. Rein Therapeutics Inc. has a 1 year low of $0.89 and a 1 year high of $2.18. The company has a market cap of $81.94 million, a price-to-earnings ratio of -0.50 and a beta of 1.35.

Rein Therapeutics (NASDAQ:RNTX) last released its earnings results on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.30. Research analysts expect that Rein Therapeutics Inc. will post -0.53 earnings per share for the current year.

Analyst Ratings Changes

RNTX has been the subject of several analyst reports. HC Wainwright decreased their price objective on Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Monday, June 1st. Wall Street Zen upgraded Rein Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Rein Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.